Hematologic Oncology

The FDA has accepted a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

Zanubrutinib yielded sustained progression-free survival and a tolerable safety profile in older patients with CLL/SLL treated in the SEQUOIA trial.

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML.

Gilteritinib generated comparable OS outcomes vs midostaurin in newly diagnosed FLT3-mutated AML, failing to meet the phase 3 trial primary end point.

Ziftomenib plus 7+3 yielded high CR and MRD-negativity rates with manageable safety in newly diagnosed NPM1/KMT2A-mutated AML.

Obe-cel delivered durable remissions in relapsed/refractory B-ALL, with the best efficacy and safety seen in patients with low disease burden.

Epcoritamab improved PFS and produced durable complete responses vs chemoimmunotherapy in relapsed/refractory large B-cell lymphoma.

RevCAR T did not cause GVHD or ICANS and achieved complete remission in patients with CD123-positive relapsed/refractory AML.

A phase 2 study of dose-adjusted EPOCH plus tafasitamab with or without rituximab met its primary end point of MRD negativity after the first cycle.

Branko Cuglievan, MD, discusses data for revumenib in the pediatric R/R KMT2AR-acute leukemias subgroup from AUGMENT-101.

Jennifer Marvin-Peek, MD, discusses data for azacitidine, venetoclax, and ivosidenib, in IDH1-mutated acute myeloid leukemia and their significance.

Revumenib yielded responses across subgroups with relapsed/refractory, NPM1-mutated AML and co-mutations, as well as in KMT2A-rearranged acute leukemia.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Check out some of the top oncology news and trends of the week.

Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.

The FDA has approved orally disintegrating nilotinib tablets for select patients with chronic myeloid leukemia.

Tafasitamab plus lenalidomide and R-CHOP showed significant PFS improvements compared with R-CHOP alone in diffuse large B-cell lymphoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm.

Alex Herrera, MD, discusses safety data and considerations for nivolumab plus AVD in classical hodgkin lymphoma.